- Develop and implement bioinformatics analysis strategy for tumor target antigen discovery in CAR and TCR pipelines.- Drive development activities, identify and address computational and statistical challenges in the analysis pipelines.- Develop best-practice bioinformatic analysis protocols for data storage and analysis result reproducibility.- Develop computational methods and pipelines to analyze large-scale in-house and publicly available next generation sequencing data and support the pre-clinical development of transformative cell therapy assets.- Interface with other research teams engaged in molecular biology, cell biology, high throughput screening, and early process development to address critical issues, relevant ideas, and unmet needs from a clinical perspective for renewed discovery and analytical efforts.- Establish computing infrastructure, analysis pipelines, and algorithms for omics datasets, including WGS, WES, RNA-Seq, TCR-Seq, single-cell omics and CRISPR screening.- Collaborate with vector development, CAR-T, CAR-NK, and TCR-T programs.

ScreeningPrecision oncology, tumor profiling, liquid biopsy, bioinformatics, NGS.- Designed and defended analytical experiments with clinical samples.- Developed statistical methods and procedures, described and validated Guardant’stechnologies.- Wrote experimental protocols and reported in collaboration with assay developmentscientists.- Supported the increasing scale of running many thousands of samples per year byimplementing appropriate QC and validation methods.- Proposed and presented detailed designs and concise, well-written reports to a cross-functionalteams.

Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies- Developed bioinformatics data standards and guidance for scientific and regulatory reviews of OTAT. - Performed bioinformatics data analyses using internally developed tools as well as open-source software and prediction algorithms.- Evaluated NGS and other bioinformatics datasets/pipelines relevant to the development of advanced individualized cell and gene therapy products submitted to OTAT.- Communicated results to FDA scientists, collaborators, and external stakeholders.- Established neoantigen discovery validation pipeline and recommended reporting standards.

[1 talk, 6 publications, 5 posters]Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology- Established antibiotic resistance pipelines by customizing and assembling various tools like Hexagon, Blast, genome assembler (SPAdes), Resistance Gene Identifier (RGI) and Comprehensive Antibiotic Resistance Database (CARD) to examine and visualize safety profiles of biologics products for CBER regulatory work. - Identified SNP biomarkers that may differentially affect arthroplasty related adverse events in sex/race-stratified subpopulations by mining real world evidence data such as patients’ clinical diagnosis/history/outcome and their demographic and genetic information from Electronic Medical Records and Genomics (eMERGE) network dataset. This work was collaborated with NIH/NHGRI.- Investigated into sequences and mutations of a variety of SARS-CoV-2 strains to choose a representative set of strains for diagnostic test validation.- Discovered cell surface antigens that can segregate the most restorative retinal pigment epithelium (RPE) stem cells to treat aged-related macular degeneration (AMD) in rat models by exploring differentially expressed genes and corresponding pathways across various stages of RPE cells. - Characterized human colorectal tumor subtypes by exploring differential expression, variant identification and functional annotations. - Prepared manuscripts for publication as well as technical documentation.

Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology - Studied liver toxicity effects of Vem (BRAF inhibitor) and Ipi (CTLA4 Ab) as a combination therapy for melanoma. Applied NGS technology to explore underlying mechanisms and novel biomarkers to stratify patients for better/precise treatment and outcomes. - Ran large-scale genomic datasets for analyses related to FDA projects and collaborated with researchers in the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH). - Employed statistical approaches to interpret information from high-throughput data. Applied tools within and outside the High-Performance Integrated Virtual Environment (HIVE) environment in order to address biological questions.

[1 talk]- Identified novel isoform targets in various cancer indications by mining public RNAseq datasets (TCGA, CCLE, GTEX and BLUEPRINT). Developing informative indexes and function-related annotations to improve ranking algorithm (for antibody drug conjugate and immune therapeutics). - Scientific lead of project team that was developing an enterprise tool antibody validation system for collecting / sharing information of internally-used commercial antibodies and validation results.- Collaborated with CART and Cell and Gene therapy developmental team to establish Virus/T-cell/CART annotation system, barcode label printing, experimental metadata collection, assay data capturing, data aggregation and Spotfire visualization template development.- Worked on Biologics Data Pipeline Project under NIBR Informatics Discovery Biology Informatics Group (IS Beta) as a business analyst. - Collected requirements in biology domain, providing integrated informatics solutions and consulting service to project teams in various disease areas across NIBR (e.g. IO, ONC, OPH, CVM, MSD,...).- Involved in in vivo study sample registration project to support current business workflows in between pharmacology, pathology/histology and genomics labs.

[8 publications, 4 talks, 4 posters]- Established molecular recognition feature (MoRF) databases and investigated the underlying regulatory mechanisms including alternative splicing events and posttranslational modifications.- Explored the binding diversity of intrinsically disordered proteins and integrated various bioinformatics algorithms, sequence/structure analysis and visualization tools to study the motif patterns and conformational changes of binding interfaces within protein interaction networks. - Developed novel approaches to identify biomarkers or druggable protein interactions in order to intervene disease signaling pathways by rational “unstructure-based drug design” and large scale genomics/proteomics data analyses (translational medicine).

[1 publication]- Carried out molecular dynamics simulations and Molecular Mechanic/Poisson-Boltzmann Surface Area (MM-PBSA) analysis to investigate the binding affinity of protein-protein interactions. Participated in protein interaction interface re-design.

- Developed a robotic algorithm to build a representative structural domain database based on sequence comparisons and domain assignment methods.

[1 publication]- Developed/maintained/IT-supported online bioinformatics databases, applications and webservers in the molecular bioinformatics center and helped manage/propose research grants.

- Constructed statistical/mathematical models to predict protein relative solvent accessibility from amino acid sequence (by machine learning approaches e.g. support vector machine).

Adaptive Intelligent Internet Agents Lab, Institute of Information Science- Applied the web wrapper agent toolbox to bioinformatics research (application support).

- Annotated a knowledge information sharing system based on object-oriented software engineering.

- Case studied on drug abuse incidents and related healthcare/clinical data.

- Interviewed, reported and edited information technology news as a journalist.

- Co-led the team and did epidemiological studies and health behavior survey regarding to the prevalence, accessibility, satisfaction and health education of cervical smear tests in Xikou County.